Ian Johnson

Life Sciences

Ian has spent his business career in life science. He was founder and CEO of Biotrace International plc, a leading provider of rapid microbial testing systems and reagents. Biotrace was a listed company in which Harwood was a major holder of shares until its sale to 3M in December 2006. Ian is non-executive chairman of two investments of Harwood Private Equity: Celsis Group (a public-to-private investment); and Cyprotex plc (a PIPE expansion capital investment). He is also non-executive chairman of life science company Lumora Ltd. Ian has served on the boards of various public and private companies in strategic consultancy and business development capacities including: Evans Analytical Group, MyCelx Technologies Corporation and AOI Medical Inc.. Ian studied at University College Cardiff obtaining an M.Sc. by thesis in Microbiology. He is a chartered biologist, a member of the Institute of Biology and of the Institute of Directors, and is the author of numerous publications and patents in the field of rapid microbiological testing.